{
    "root": "2346b7f5-b2c1-45f0-9f8f-5cbb4b202857",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "OSENI",
    "value": "20250228",
    "ingredients": [
        {
            "name": "ALOGLIPTIN BENZOATE",
            "code": "EEN99869SC"
        },
        {
            "name": "PIOGLITAZONE HYDROCHLORIDE",
            "code": "JQT35NPK6C"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (90000 WAMW)",
            "code": "UKE75GEA7F"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "CARNAUBA WAX",
            "code": "R12CBM0EIZ"
        },
        {
            "name": "POLYGLYCERYL-10 OLEATE",
            "code": "55C81W76DH"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        }
    ],
    "indications": "oseni indicated adjunct diet exercise improve glycemic control adults type 2 diabetes mellitus .",
    "contraindications": "obtain liver tests prior initiation . oseni may taken without food . ( 2.1 ) individualize starting dose oseni based patient \u2019 current regimen concurrent medical condition exceed daily dose alogliptin 25 mg pioglitazone 45 mg. ( 2.2 ) recommended starting patients nyha class ii congestive heart failure 25 mg alogliptin 15 mg pioglitazone ( 2.4 ) prior initiation , assess renal function creatinine clearance ( crcl ) ( 2.3 ) mild renal impairment ( creatinine clearance [ crcl ] \u226560 ml/min ) : recommended patients normal renal function . moderate renal impairment ( crcl \u226530 < 60 ml/min ) : 12.5 mg alogliptin 30 mg pioglitazone daily . severe renal impairment ( crcl \u226515 < 30 ml/min ) esrd ( crcl < 15 ml/min requiring hemodialysis ) : recommended .",
    "warningsAndPrecautions": "oseni tablets available following strengths packages : 25 mg/15 mg tablet : yellow , round , biconvex film-coated \u201c a/p \u201d \u201c 25/15 \u201d printed one side , available : ndc 64764-251-03 bottles 30 tablets ndc 64764-251-04 bottles 90 tablets ndc 64764-251-05 bottles 500 tablets 25 mg/30 mg tablet : peach , round , biconvex film-coated \u201c a/p \u201d \u201c 25/30 \u201d printed one side , available : ndc 64764-253-03 bottles 30 tablets ndc 64764-253-04 bottles 90 tablets ndc 64764-253-05 bottles 500 tablets 25 mg/45 mg tablet : red , round , biconvex , film-coated \u201c a/p \u201d \u201c 25/45 \u201d printed one side , available : ndc 64764-254-03 bottles 30 tablets ndc 64764-254-04 bottles 90 tablets ndc 64764-254-05 bottles 500 tablets 12.5 mg/30 mg tablet : pale peach , round , biconvex film-coated \u201c a/p \u201d \u201c 12.5/30 \u201d printed one side , available : ndc 64764-123-03 bottles 30 tablets ndc 64764-123-04 bottles 90 tablets ndc 64764-123-05 bottles 500 tablets",
    "adverseReactions": "oseni contraindicated patients : established nyha class iii iv heart failure time oseni initiation [ boxed warning ] . history serious hypersensitivity reaction alogliptin , pioglitazone , excipients oseni . anaphylaxis , angioedema severe cutaneous reported [ ( 5.3 ) , ( 6.2 ) ] .",
    "indications_original": "OSENI is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
    "contraindications_original": "Obtain liver tests prior to initiation. OSENI may be taken with or without food. ( 2.1 ) Individualize the starting dose of OSENI based on the patient\u2019s current regimen and concurrent medical condition but do not exceed a daily dose of alogliptin 25 mg and pioglitazone 45 mg. ( 2.2 ) The recommended starting dosage in patients with NYHA Class I or II congestive heart failure is 25 mg of alogliptin and 15 mg of pioglitazone ( 2.4 ) Prior to initiation, assess renal function with creatinine clearance (CrCl) ( 2.3 ) Mild renal impairment (creatinine clearance [CrCl] \u226560 mL/min): same as the recommended dosage in patients with normal renal function. Moderate renal impairment (CrCl \u226530 to <60 mL/min): 12.5 mg of alogliptin and 30 mg of pioglitazone once daily. Severe renal impairment (CrCl \u226515 to <30 mL/min) or ESRD (CrCl <15 mL/min or requiring hemodialysis): not recommended.",
    "warningsAndPrecautions_original": "OSENI tablets are available in the following strengths and packages:\n                  25 mg/15 mg tablet: yellow, round, biconvex and film-coated with both \u201cA/P\u201d and \u201c25/15\u201d printed on one side, available in:\n                  \n                     \n                     \n                     \n                        \n                           \n                              NDC 64764-251-03\n                           \n                           \n                              Bottles of 30 tablets\n                           \n                        \n                        \n                           \n                              NDC 64764-251-04\n                           \n                           \n                              Bottles of 90 tablets\n                           \n                        \n                        \n                           \n                              NDC 64764-251-05\n                           \n                           \n                              Bottles of 500 tablets\n                           \n                        \n                     \n                  \n                  25 mg/30 mg tablet: peach, round, biconvex and film-coated with both \u201cA/P\u201d and \u201c25/30\u201d printed on one side, available in:\n                  \n                     \n                     \n                     \n                        \n                           \n                              NDC 64764-253-03\n                           \n                           \n                              Bottles of 30 tablets\n                           \n                        \n                        \n                           \n                              NDC 64764-253-04 \n                           \n                           \n                              Bottles of 90 tablets\n                           \n                        \n                        \n                           \n                              NDC 64764-253-05\n                           \n                           \n                              Bottles of 500 tablets\n                           \n                        \n                     \n                  \n                  25 mg/45 mg tablet: red, round, biconvex, film-coated and with both \u201cA/P\u201d and \u201c25/45\u201d printed on one side, available in:\n                  \n                     \n                     \n                     \n                        \n                           \n                              NDC 64764-254-03\n                           \n                           \n                              Bottles of 30 tablets\n                           \n                        \n                        \n                           \n                              NDC 64764-254-04\n                           \n                           \n                              Bottles of 90 tablets\n                           \n                        \n                        \n                           \n                              NDC 64764-254-05\n                           \n                           \n                              Bottles of 500 tablets\n                           \n                        \n                     \n                  \n                  12.5 mg/30 mg tablet: pale peach, round, biconvex and film-coated with both \u201cA/P\u201d and \u201c12.5/30\u201d printed on one side, available in:\n                  \n                     \n                     \n                     \n                        \n                           \n                              NDC 64764-123-03\n                           \n                           \n                              Bottles of 30 tablets\n                           \n                        \n                        \n                           \n                              NDC 64764-123-04\n                           \n                           \n                              Bottles of 90 tablets\n                           \n                        \n                        \n                           \n                              NDC 64764-123-05\n                           \n                           \n                              Bottles of 500 tablets",
    "adverseReactions_original": "OSENI is contraindicated in patients with:\n                  \n                     Established NYHA Class III or IV heart failure at the time of OSENI initiation [see Boxed Warning].\n                     A history of serious hypersensitivity reaction to alogliptin, pioglitazone, or any of the excipients in OSENI. Reactions such as anaphylaxis, angioedema and severe cutaneous adverse reactions have been reported [see Warnings and Precautions (5.3), Adverse reactions (6.2)]."
}